Fidaxomicin: a minimally absorbed macrocyclic antibiotic for the treatment ofClostridium difficileinfections
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Fidaxomicin: a minimally absorbed macrocyclic antibiotic for the treatment ofClostridium difficileinfections
Authors
Keywords
-
Journal
Expert Review of Anti-Infective Therapy
Volume 11, Issue 8, Pages 767-776
Publisher
Informa UK Limited
Online
2013-08-27
DOI
10.1586/14787210.2013.814767
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Age on Treatment Outcomes inClostridium difficileInfection
- (2013) Thomas J. Louie et al. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
- Fidaxomicin: A novel macrocyclic antibiotic for the treatment of Clostridium difficile infection
- (2012) T. Crawford et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Fidaxomicin in the Treatment of Clostridium difficile-Associated Diarrhoea
- (2012) James Greig CLINICAL DRUG INVESTIGATION
- Safety Analysis of Fidaxomicin in Comparison With Oral Vancomycin for Clostridium difficile Infections
- (2012) K. Weiss et al. CLINICAL INFECTIOUS DISEASES
- Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI
- (2012) T. J. Louie et al. CLINICAL INFECTIOUS DISEASES
- Reduced Acquisition and Overgrowth of Vancomycin-Resistant Enterococci and Candida Species in Patients Treated With Fidaxomicin Versus Vancomycin for Clostridium difficile Infection
- (2012) M. M. Nerandzic et al. CLINICAL INFECTIOUS DISEASES
- Fidaxomicin Inhibits Spore Production in Clostridium difficile
- (2012) Farah Babakhani et al. CLINICAL INFECTIOUS DISEASES
- Fidaxomicin Is an Inhibitor of the Initiation of Bacterial RNA Synthesis
- (2012) Irina Artsimovitch et al. CLINICAL INFECTIOUS DISEASES
- Fidaxomicin "Chaser" Regimen Following Vancomycin for Patients With Multiple Clostridium difficile Recurrences
- (2012) S. Johnson et al. CLINICAL INFECTIOUS DISEASES
- Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials
- (2012) Derrick W. Crook et al. CLINICAL INFECTIOUS DISEASES
- Current Status of Clostridium difficile Infection Epidemiology
- (2012) F. C. Lessa et al. CLINICAL INFECTIOUS DISEASES
- Changing Epidemiology of Clostridium difficile Infection Following the Introduction of a National Ribotyping-Based Surveillance Scheme in England
- (2012) M. H. Wilcox et al. CLINICAL INFECTIOUS DISEASES
- Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin
- (2012) O. A. Cornely et al. CLINICAL INFECTIOUS DISEASES
- Burden of Clostridium difficile on the Healthcare System
- (2012) Erik R. Dubberke et al. CLINICAL INFECTIOUS DISEASES
- Epidemiology and Healthcare Costs of Incident Clostridium difficile Infections Identified in the Outpatient Healthcare Setting
- (2012) Jennifer L. Kuntz et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Burden of Clostridium difficile Infection in Long-Term Care Facilities in Monroe County, New York
- (2012) Deepa Pawar et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Fidaxomicin inhibits toxin production in Clostridium difficile
- (2012) F. Babakhani et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Risk factors for mortality in Clostridium difficile infection in the general hospital population: a systematic review
- (2012) M.G. Bloomfield et al. JOURNAL OF HOSPITAL INFECTION
- Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial
- (2012) Oliver A Cornely et al. LANCET INFECTIOUS DISEASES
- A Real-World Evaluation of Oral Vancomycin for Severe Clostridium difficile Infection: Implications for Antibiotic Stewardship Programs
- (2012) Frank Le et al. PHARMACOTHERAPY
- Postantibiotic Effect of Fidaxomicin and Its Major Metabolite, OP-1118, against Clostridium difficile
- (2011) Farah Babakhani et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Comparative Susceptibilities to Fidaxomicin (OPT-80) of Isolates Collected at Baseline, Recurrence, and Failure from Patients in Two Phase III Trials of Fidaxomicin against Clostridium difficile Infection
- (2011) Ellie J. C. Goldstein et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent Infections
- (2011) Kathleen M. Mullane et al. CLINICAL INFECTIOUS DISEASES
- Fidaxomicin: A Novel Macrocyclic Antibiotic Approved for Treatment of Clostridium difficile Infection
- (2011) A. A. Venugopal et al. CLINICAL INFECTIOUS DISEASES
- Cumulative Antibiotic Exposures Over Time and the Risk of Clostridium difficile Infection
- (2011) V. Stevens et al. CLINICAL INFECTIOUS DISEASES
- The economic burden of Clostridium difficile
- (2011) S.M. McGlone et al. CLINICAL MICROBIOLOGY AND INFECTION
- Comparison of the Burdens of Hospital-Onset, Healthcare Facility-Associated Clostridium difficile Infection and of Healthcare-Associated Infection due to Methicillin-Resistant Staphylococcus aureus in Community Hospitals
- (2011) Becky A. Miller et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Fidaxomicin versus Vancomycin forClostridium difficileInfection
- (2011) Thomas J. Louie et al. NEW ENGLAND JOURNAL OF MEDICINE
- Update on Clostridium difficile infection
- (2010) Caoilfhionn OʼDonoghue et al. CURRENT OPINION IN GASTROENTEROLOGY
- Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)
- (2010) Stuart H. Cohen et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Economic healthcare costs of Clostridium difficile infection: a systematic review
- (2010) S.S. Ghantoji et al. JOURNAL OF HOSPITAL INFECTION
- Health Care–AssociatedClostridium difficileInfection in Canada: Patient Age and Infecting Strain Type Are Highly Predictive of Severe Outcome and Mortality
- (2009) Mark Miller et al. CLINICAL INFECTIOUS DISEASES
- European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI)
- (2009) M.P. Bauer et al. CLINICAL MICROBIOLOGY AND INFECTION
- Safety, Tolerance, and Pharmacokinetic Studies of OPT-80 in Healthy Volunteers following Single and Multiple Oral Doses
- (2008) Y. K. Shue et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical Outcomes, Safety, and Pharmacokinetics of OPT-80 in a Phase 2 Trial with Patients with Clostridium difficile Infection
- (2008) T. Louie et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- OPT-80 Eliminates Clostridium difficile and Is Sparing of Bacteroides Species during Treatment of C. difficile Infection
- (2008) T. J. Louie et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Both Oral Metronidazole and Oral Vancomycin Promote Persistent Overgrowth of Vancomycin-Resistant Enterococci during Treatment of Clostridium difficile-Associated Disease
- (2008) W. N. Al-Nassir et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Emergence ofClostridium difficileInfection Due to a New Hypervirulent Strain, Polymerase Chain Reaction Ribotype 078
- (2008) Abraham Goorhuis et al. CLINICAL INFECTIOUS DISEASES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started